Stockscreener 앱 받기
3.50
3.86%
0.13
Trevi Therapeutics Inc 주식(TRVI)의 최신 뉴스
Trevi Therapeutics, Inc. to Post Q3 2024 Earnings of ($0.12) Per Share, Leerink Partnrs Forecasts (NASDAQ:TRVI) - MarketBeat
Trevi Therapeutics, Inc. Expected to Earn Q1 2025 Earnings of ($0.11) Per Share (NASDAQ:TRVI) - MarketBeat
Leerink Partnrs Upgrades Trevi Therapeutics (NASDAQ:TRVI) to "Strong-Buy" - MarketBeat
Trevi Therapeutics (NASDAQ:TRVI) Coverage Initiated by Analysts at Leerink Partners - Defense World
Trevi Therapeutics CEO sells over $18,000 in company stock - Investing.com
Insider Selling: Trevi Therapeutics, Inc. (NASDAQ:TRVI) CEO Sells 4,219 Shares of Stock - MarketBeat
Trevi Therapeutics (NASDAQ:TRVI) Coverage Initiated at Leerink Partners - MarketBeat
Why Trevi Therapeutics Could Be a Triple-Bagger Biotech Stock - sharewise
Why Trevi Therapeutics Could Be a Triple-Bagger Biotech Stock - MSN
Why Trevi Therapeutics Could Be a Triple-Bagger Biotech Stock - MarketBeat
Trevi Therapeutics, Inc. (NASDAQ:TRVI) CEO Sells $33,162.62 in Stock - MarketBeat
Trevi Therapeutics Announces Oral Presentation on Data from Ph2a CANAL Trial at the European Respiratory Society Congress 2024 - Citizentribune
Trevi Therapeutics Announces Oral Presentation on Data from Ph2a CANAL Trial at the European Respiratory Society Congress 2024 – Company Announcement - Financial Times
Trevi Therapeutics Announces Oral Presentation on Data from Ph2a CANAL Trial at the European Respiratory Society Congress 2024 - StockTitan
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives $7.80 Average Target Price from Analysts - Defense World
Trevi Therapeutics shares rise on bullish analyst initiation By Investing.com - Investing.com Canada
Raymond James initiates Trevi Therapeutics at Outperform, sees first-to-market opportunity for Haduvio - Investing.com Canada
Trevi Therapeutics (NASDAQ:TRVI) Research Coverage Started at Raymond James - MarketBeat
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Trevi Therapeutics (NASDAQ:TRVI) Coverage Initiated at Raymond James - Defense World
Insider Selling: Trevi Therapeutics, Inc. (NASDAQ:TRVI) Director Sells 4,555 Shares of Stock - MarketBeat
Trevi therapeutics director Meeker sells shares worth over $13,000 - Investing.com
Trevi Therapeutics to Participate in September Investor and Medical Conferences - PR Newswire
Trevi Therapeutics to Participate in September Investor and Medical Conferences - StockTitan
Trevi Therapeutics executive sells shares worth over $48,000 - Investing.com India
Trevi Therapeutics executive sells shares worth over $48,000 - Investing.com
Trevi Therapeutics executive sells shares worth over $48,000 By Investing.com - Investing.com UK
Trevi Therapeutics (NASDAQ:TRVI) Upgraded to "Strong-Buy" at EF Hutton Acquisition Co. I - MarketBeat
EF Hutton Acquisition Co. I Upgrades Trevi Therapeutics (NASDAQ:TRVI) to Strong-Buy - Defense World
Trevi Therapeutics Provides Business Updates - GuruFocus.com
EF Hutton initiates coverage on Trevi Therapeutics shares with Buy rating - Investing.com Canada
Price T Rowe Associates Inc. MD Purchases Shares of 13,561 Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Thomas Sciascia Sells 18,660 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) Stock - Defense World
Trevi Therapeutics executive trades over $130k in company stock By Investing.com - Investing.com Australia
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Insider Thomas Sciascia Sells 18,660 Shares - MarketBeat
Trevi Therapeutics executive trades over $130k in company stock - Investing.com
Trevi Therapeutics executive trades over $130k in company stock By Investing.com - Investing.com UK
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Shares Purchased by Vanguard Group Inc. - Defense World
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Expected to Earn Q3 2024 Earnings of ($0.09) Per Share - MarketBeat
Trevi Therapeutics to Participate in Upcoming September Events - GuruFocus.com
B. Riley Research Analysts Decrease Earnings Estimates for Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Trevi Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates - Longview News-Journal
Trevi Therapeutics Announces the Initiation of its Phase 2b CORA - GuruFocus.com
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q2 2024 Earnings Call Transcript - Insider Monkey
Earnings call: Trevi Therapeutics reports progress in chronic cough trials By Investing.com - Investing.com Australia
Earnings call: Trevi Therapeutics reports progress in chronic cough trials - Investing.com
Earnings call: Trevi Therapeutics reports progress in chronic cough trials By Investing.com - Investing.com Canada
Trevi Therapeutics, Inc. (TRVI) Q2 2024 Earnings Call Transcript - Seeking Alpha
Trevi Therapeutics to Report Q1 2023 Financial Results and Provide a Corporate Update on May 11, 2023 - Quantisnow
TRVI Stock Earnings: Trevi Therapeutics Misses EPS for Q2 2024 - InvestorPlace
Trevi Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates Reaffirming Clinical Trial Guidance - Manchestertimes
Trevi Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates Reaffirming Clinical Trial Guidance - PR Newswire
Trevi Therapeutics Announces Pricing of $[50 Million] Public Offering - Quantisnow
Institutional investors in Trevi Therapeutics, Inc. (NASDAQ:TRVI) see US$40m decrease in market cap last week, although long-term gains have benefitted them. - Yahoo Finance
TRVITrevi Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Trevi Therapeutics (TRVI) to Release Quarterly Earnings on Thursday - MarketBeat
Trevi Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on August 8, 2024 - Marketscreener.com
Chronic Refractory Cough Pipeline 2024 | GSK, Trevi Therapeutics - openPR
Work at The Globe - The Globe and Mail
Trevi Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on August 8, 2024 – Company AnnouncementFT.com - Financial Times
Trevi Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on August 8, 2024 - StockTitan
SG Americas Securities LLC Lowers Holdings in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Short Interest in Trevi Therapeutics, Inc. (NASDAQ:TRVI) Rises By 32.6% - MarketBeat
With 37% ownership in Trevi Therapeutics, Inc. (NASDAQ:TRVI), institutional investors have a lot riding on the business - Simply Wall St
Analyzing Trevi Therapeutics Inc (TRVI) After Recent Trading Activity - Knox Daily
Trevi Therapeutics Inc Inc. (TRVI) Price Performance Over the Years: A Comparative Study - The InvestChronicle
1.26%
1.71%
자본화:
|
볼륨(24시간):